RBC Capital analyst Brian Abrahams lowered the firm’s price target on Karyopharm (KPTI) to $19 from $30 and keeps an Outperform rating on the shares. The company reported a solid quarter for Xpovio sales, while the reduction of financing overhangs, and MF timelines intact for March 2026 make for a favorable risk/reward setup, the analyst tells investors in a research note. RBC adds however that its reduced price target reflects the recent financing transactions.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
- Karyopharm Therapeutics Reports Q3 2025 Financial Results
- Karyopharm files to sell 9.57M shares of common stock for holders
- Karyopharm files to sell 2.81M shares of common stock for holders
- Karyopharm reports Q3 EPS ($3.82), consensus ($3.25)
- Karyopharm sees FY25 revenue $140M-$155M, consensus $150.22M